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ABSTRACT
Introduction: Older people often use medications with
anticholinergic or sedative side effects which increase
the risk of falling and worsen cognitive impairment.
The Drug Burden Index (DBI) is a measure of the
burden of anticholinergic and sedative medications.
Medication reviews are typically done by a pharmacist
in collaboration with a general practitioner to optimise
the medication use and reduce these adverse drug
events. We will evaluate whether a Multidisciplinary
Multistep Medication Review (3MR) is an effective
intervention to reduce a patient’s DBI.
Methods: A randomised controlled trial including 160
patients from 15 community pharmacies will be
conducted. Per pharmacy, 1 pharmacist will perform a
structured 3MR in close collaboration with the general
practitioner, including the objective to reduce the DBI.
Analysis: Primary outcome—the difference in
proportion of patients having a decrease in DBI≥0.5 in
the intervention and control groups at follow-up.
Secondary outcomes—anticholinergic and sedative
side effects, falls, cognitive function, activities of daily
living, quality of life, hospital admission, and mortality.
Ethics and dissemination: The burden of patients
will be kept at a minimum. The 3MR can be considered
as usual care by the pharmacist and general
practitioner. Medical specialists will be consulted, if
necessary. The intervention is specifically aimed at
older community-dwelling patients in an attempt to
optimise prescribing, in particular, to reduce
medication with anticholinergic and sedative properties.
Study results will be published in peer-reviewed
journals and will be distributed through information
channels targeting professionals.
Trial registration number: NCT02317666;
Pre-results.
INTRODUCTION
Older individuals use more medications than
any other age group.1 They typically suffer
from multiple acute and chronic diseases,
which often necessitates the use of multiple
concomitant medications.2 Polypharmacy in
combination with age-related pharmacoki-
netic and pharmacodynamic changes, such
as decrease in renal function and altered
drug responsiveness, predisposes older indivi-
duals to an increased risk of drug–drug inter-
actions, drug–disease interactions, adverse
drug events and potentially inappropriate
prescribing (PIP).3–5 Many PIP instances are
attributable to medication with anticholiner-
gic and/or sedative properties.6 7 Those medi-
cations increase the risk of falls in older
people and worsen cognitive impairment,
resulting in problems in activities of daily
living (ADL).8–11 Around 600 medications are
known to have anticholinergic effects to a
greater or lesser extent,12 and many of these
are widely used among older people, espe-
cially cardiovascular medication13 14 and med-
icines acting on the central nervous system.
Hypnotics and sedatives are among the most
commonly used psychotropic medications,
especially in the very old.15 A Finnish study
found that almost one-third of adults aged
>75 years used anxiolytic or hypnotic medica-
tion, and almost one-tenth used antidepres-
sant or antipsychotic medicines.16 Given these
ﬁndings, decreasing the exposure to anti-
cholinergic and sedative medications is likely
to result in important health beneﬁts for
older people. The Drug Burden Index
(DBI) calculates an individual patient’s expos-
ure to anticholinergic and sedative medica-
tions taking into account the medicine
dosage.17 A recent literature review shows that
the DBI is associated with impairments in
physical and cognitive functions of older
individuals.18 19
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Medication reviews are seen as a promising strategy to
enhance the quality of prescribing, although there is still
a lack of evidence on cost or clinical effectiveness.
Medication reviews could be made more effective by tar-
geting high-risk groups and focusing on medicines which
could be safely stopped.20–23 According to Dutch guide-
lines, a medication review is a structured critical examin-
ation of a patient’s medication, done by a pharmacist and
a general practitioner (GP), to reach an agreement with
the patient about treatment, optimising the effectiveness
of the medicines, and minimising the number of
medication-related problems.24 Annual Multidisciplinary
Multistep Medication Reviews (3MR) are recommended
for older chronic polypharmacy patients with additional
risk factors. However, criteria used so far—living in a
nursing home, decreased renal clearance (estimated
glomerular ﬁltration rate <50/mL/min/1.73 m2),
decreased cognitive function, increased risk of falling,
signals of decreased medication adherence or unplanned
hospital admission24 —form an inadequate demarcation
of the high-risk population. Therefore, in the present
study, we used the DBI to identify high-risk patients who
could beneﬁt from medication reviews. The aim of our
study is to evaluate whether a 3MR is an effective inter-
vention to reduce a patient’s DBI.
METHODS AND ANALYSIS
Study design
A single-blinded randomised controlled trial will be con-
ducted in line with the ‘Consolidated Standards of
Reporting Trials (CONSORT)’statement (https://www/
consort-statement.org) and the ‘Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT)’criteria (https://www.spirit-statement.rug).
Patients will be recruited from pharmacies and will be
randomly allocated into control group and intervention
group (refer to Selection process, randomisation, inter-
vention allocation and blinding section). The interven-
tion consists of a 3MR conducted by the pharmacist in
collaboration with the GP. The main aim of the medica-
tion review is to optimise the patient’s medication with a
focus on lowering the DBI by reducing medication with
anticholinergic and sedative properties. Participants in
the control group will receive the 3MR after the study
period (postponed intervention). Primary and second-
ary study outcomes will be determined for intervention
group and control group at baseline and at 3 months of
follow-up after the intervention.
Participants and setting
Our aim is to enrol a minimum of 160 participants from
15 community pharmacies in the region of Groningen,
the Netherlands (see Sample size calculation section).
We will approach a total of 400 patients to recruit about
160 participants. One pharmacist will conduct the medi-
cation reviews in each pharmacy. As one community
pharmacy is mostly associated with several medical
practices, the pharmacist will collaborate with different
GPs, but with only one GP for each patient.
Pharmacists
Inclusion criteria
▸ Established collaboration with the GP
▸ Experience with medication reviews (accredited com-
munity pharmacist or registered pharmacist in train-
ing to be accredited).
Participants
Inclusion criteria
▸ Aged ≥65 years
▸ Living independently
▸ Chronic polypharmacy (≥5 medications for ≥3
months24 and DBI≥1)
▸ Use of at least one medication with ATC N05 or N06
▸ Written informed consent (IC)
Exclusion criteria
▸ Palliative care only
▸ Limited life expectancy (<3 months)
▸ Urgently in need of a medication review
▸ No Dutch language skills
▸ Advanced dementia
▸ Received a medication review within 9 months before
the study period.
Sample size calculation
A minimum of ∼160 participants (80 in the control
group and 80 in the intervention group) will be sufﬁ-
cient to detect a medium effect size with a power of
80%, an α of 5% on the primary outcome, and an intra-
class correlation coefﬁcient up to 0.2.25 To the best of
our knowledge, only one pilot randomised study has
been conducted that was aimed at decreasing the DBI.26
We, therefore, cannot estimate an effect size ‘a priori’ as
this should be based on multiple independent studies.
Since a small effect size will probably be clinically irrele-
vant and a large effect size may be unrealistic, we chose
a medium effect size. With the aim to include 160
patients and the expectation of a non-response rate of
60%, we will invite a total of 400 participants.
INTERVENTION
The intervention will be a 3MR carried out by the
pharmacist in close collaboration with the GP and if
needed, with medical specialists. The medication reviews
will be based on current Dutch guidelines with a focus
on lowering the load of anticholinergic/sedative medica-
tion following ﬁve steps as outlined below.24 Pharmacy
students will be assisting the community pharmacists
during some steps of the reviews. Participants in the
control arm will receive their medication review after
the follow-up measurement. All participants have been
informed about the possible delay of their medication
review as part of the IC procedure.
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Step 1: pharmacotherapeutic anamnesis
The pharmacist collects information about the actual
medication use, problems with the medication use,
and experiences, efﬁcacy and possible side effects of
the medication—in particular anticholinergic and
sedative medication—during a face-to-face consult-
ation with the patient. Furthermore, the use of
‘over-the-counter’ medication, and patients’ expecta-
tions and preferences about their medication will be
discussed.
Step 2: pharmacotherapeutic medication review
The pharmacist identiﬁes potential pharmacotherapeu-
tic problems considering the patient’s characteristics
and experiences, life expectancy, and preferences using
PIP tools such as the STOPP and START criteria.6 The
pharmacist will draft recommendations for the GP.
Different problems and/or recommendations will be
prioritised. Recommendations could include to start or
stop medication, change doses or carry out additional
laboratory tests.
Step 3: multidisciplinary meeting
The pharmacist discusses the patient’s medication
proﬁle with the GP during a face-to-face meeting.
Together, they will draft an action plan, including treat-
ment objectives, potential actions, and priority of actions
(eg, withdrawing medication). Preferences of the
patient, patient characteristics, experience, and life
expectancy will be central in the decision-making
process. If needed, the appropriate medical specialists
will be included in the medication review.
Step 4: pharmaceutical action plan
The pharmacist or GP discusses the action plan, made
in step 3, with the patient. An agreement about the
action plan will be made with the patient, preferences,
expectations and concerns of the patient are key points
in the decision-making process. Time schedule for the
next intervention will be made and changes in medica-
tion treatment will be registered.
Step 5: follow-up
Actions made in step 4 are evaluated at an agreed time
interval with the pharmacist and/or GP.
Study parameters
Main study parameter
The key aim of the 3MR is to optimise a patient’s medi-
cation and to lower the DBI by reducing medications
with anticholinergic and sedative properties. The DBI
will be measured for all participants at baseline and
follow-up using electronic pharmacy dispensing records
corrected for actual medication intake based on a
double check with the patient by telephone. We will cal-




D, daily dose of a drug; δ, minimum recommended
daily dose as stated in Dutch standard reference
sources.27
All chronically used (≥3 months) medications (exclud-
ing dermatological (ATC D) and sensory medication
(ATC S)) having anticholinergic properties (including
dry mouth, constipation and urine retention) or sedative
properties based on standard Dutch reference
sources27–30 will be included in the calculation. For each
drug, the value of the DBI will range from 0 to 1
depending on the δ. The cessation of one anticholiner-
gic or sedative medication would lower the DBI by about
0.5. We consider the cessation of one drug to be clinic-
ally relevant and therefore, deﬁned the primary
outcome as the difference in proportion of patients
having a decrease of DBI≥0.5 from baseline to follow-up
in the intervention group and in the control group. It is
expected that at follow-up, the proportion of patients
with a decrease of the DBI≥0.5 is signiﬁcantly higher in
the intervention group in comparison to the control
group.
Secondary parameters
Secondary study parameters are chosen with regard to
patient outcomes. All questionnaires and tests will be
administered to all participants at baseline and follow-up
(see Study procedures section).
▸ Anticholinergic side effects: as measured by the
Undersøgelser (UKU) side effect rating scale.31
▸ Sedative side effects derived from a patient-reported
adverse drug event questionnaire.32
▸ Risk of falls: as measured by patient-reported fall inci-
dents and the ‘Up & Go’ test.33
▸ Cognitive function: as measured by the ‘Seven
Minute Screen’,34 the ‘Trailmaking Test A & B’35 and
the ‘Digit Symbol Coding Test’ of the ‘Wechsler Adult
Intelligence Scale III’.36
▸ ADL: as measured by the ‘Groningen Activiteiten
Restrictie Schaal’.37 38
▸ Quality of life: as measured by the EQ-5D-3L
questionnaire.39
▸ Hospital admission: assessed from the patient’s
medical records.
▸ Mortality: assessed from the patient’s medical
records.
Covariates
All demographic characteristics (sex, age, educational
level, marital status), and number of medications at
baseline and follow-up will be included in the analysis.
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Selection process, randomisation, intervention allocation
and blinding
A preliminary list of potentially eligible patients will be
obtained by electronic search in the electronic phar-
macy dispensing records based on a limited set of inclu-
sion criteria (age, chronic polypharmacy, use of
psychotropic medication (NO5/NO6)). Notably, patients
in the Netherlands are registered with one pharmacy, so
the pharmacies keep relatively accurate dispensing
records of all prescribed medication. Inclusion/exclu-
sion criteria will be checked by the researchers, pharma-
cists and GPs to obtain a list of eligible patients who will
be approached for IC as outlined below. Within each
pharmacy, all included patients will then be matched in
pairs by gender, age, DBI and number of medications.
Subsequently, this list of participants will be sent to the
principal investigator (KT) who is not involved in the
recruitment and data collection. Within each pair, one
participant will be randomly assigned to the intervention
condition by the principal investigator (coin ﬂipping).
The principal investigator will inform the pharmacists
about the patient’s allocation. Pharmacists and partici-
pants cannot be kept blind. All researchers involved in
data collection will be kept blind to the allocation.
Therefore, this is a single-blinded study. This method
will ensure that we have balanced groups within each
pharmacy, random allocation, and concealment of allo-
cation from the researchers involved in data collection.
Pharmacies will be enrolled continuously, and all partici-
pants of one pharmacy will be enrolled at the same
time. This excludes other methods such as stratiﬁed ran-
domisation of all participants at the same time.
Quality of data
We will collect data in a standardised manner using data
collection sheets. All researchers will be trained by an
experienced neuropsychologist. We will assess patients’
cognitive function using objective and validated neuro-
psychological tests (see Study parameters section).
Validated questionnaires will be used to assess anti-
cholinergic and sedative side effects, loss of ADL, and
quality of life (see Study parameters section).
Medication data will be collected from the pharmacy
information system and actual use will be veriﬁed by the
patient. All data will be entered in a Microsoft Access
database by a research assistant. Baseline data will be
collected before the intervention. Follow-up data will be
collected 3 months after the intervention has taken
place, assuming that within these 3 months the
maximum effect of possible medication changes made
during the 3MR are reached. All data entries will be
double-checked against hardcopy source data.
Statistical analysis
All data will be analysed in IBM SPSS V.22. Descriptive
statistics of the intervention group and control group
will be conducted. Analyses will be done ‘per protocol’
and ‘intention-to-treat’. Percentages and frequencies will
be calculated for nominal variables, median values and
IQRs, or frequencies will be calculated for ordinal data
or continuous data with a skewed distribution. Means
and SDs will be calculated for continuous data that
follow a normal distribution. Missing data will be kept at
a minimum by standardising and monitoring data collec-
tion. In case of missing data, sensitivity analyses will be
conducted to examine the inﬂuence of missing data on
the study ﬁndings. All statistical tests will be one sided.
p Values ≤0.05 will be considered signiﬁcant.
Primary study parameters
Generalised linear mixed models will be employed to
account for dependence of data (patients within phar-
macy). Consequently, a random intercept and a random
slope at the level of pharmacies will be entered into the
linear mixed model. Furthermore, we will adjust for sig-
niﬁcant covariates.
Secondary study parameters
Secondary study parameters will be examined in a
similar way. Depending on whether these are continuous
variables and their distribution is normally or Poisson
distributed, we will employ standard linear mixed
models or Poisson linear mixed models.
Study procedures
The ﬂowchart of ﬁgure 1 provides a schematic overview
of the study phases along with the participant ﬂow at
each study phase.
ETHICS AND DISSEMINATION
The ethics and dissemination are in line with a similar
study.40 The study will be conducted according to the
Declaration of Helsinki regarding the Ethical Principles
for Medical Research Involving Human Subjects
(amended by the 64th World Medical Association’s
General Assembly, Fortaleza, Brazil, October 2013), and
in accordance with Dutch medical-ethical legislation.
The community pharmacist will ask her/ his patients to
participate. Prior to participation, written IC will be
asked. The 3MR will be based on expert consensus and
the medical literature. Moreover, the 3MR will result in
high-quality treatment recommendations that will be
attained by the pharmacist and treating GP working in
close collaboration. Final treatment decisions, however,
always rest with the treating GP. We, therefore, argue
that our intervention is one of usual care based on the
latest evidence-based principles and recommendations
made in the guidelines by the Dutch society of General
Practitioners.24 The intervention is speciﬁcally aimed at
older community-dwelling pharmacy patients in an
attempt to optimise prescribing and for this study, in
particular, to reduce medication with anticholinergic
and sedative properties.41 Data will be handled and
stored. To ensure participants’ conﬁdentiality, research
data and participants’ personal data will be stored in two
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different ﬁles. Data records from both ﬁles will be linked
with an identiﬁcation number that cannot be traced to
the individual patient and their personal characteristics.
The ﬁle with patients’ personal data will be password
protected and will be safeguarded by the investigators.
To avoid scientiﬁc fraud or misconduct, all investigators
will have full access to the data.
Finally, study results will be published in peer-
reviewed journals and in newsletters for pharmacists,
news messages for the public, and on websites for pro-
fessionals. If possible, data will be published in open-
access articles or as full-text post prints in order to
make them available to the public. Duplicate publica-
tion will be avoided.
In addition, this study has been registered at http://
www.ClinicalTrials.gov (trial registration number:
NCT02317666).
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